Opexa Therapeutics, Inc. 4/A
4/A · Opexa Therapeutics, Inc. · Filed Jun 14, 2013
Insider Transaction Report
Form 4/AAmended
Warma Neil K
President & CEO
Transactions
- Award
Employee Stock Option (right to buy)
2013-02-04+95,970→ 95,970 totalExercise: $3.80Exp: 2022-01-06→ Common Stock (95,970 underlying)
Holdings
- 8,658
Common Stock
Footnotes (3)
- [F1]The attempted awards on 4-29-13 of (i) 28,571 shares of restricted common stock and (ii) an option to purchase 50,000 shares of common stock previously reported were ineffective and the awards were void ab initio.
- [F2]On January 6, 2012, the reporting person was granted an option to purchase 139,593 shares of common stock at the closing market price. The option is performance based and begins to vest quarterly over a three-year period in two tranches commencing upon Opexa achieving certain key milestones. The second tranche key milestone for vesting of 95,970 shares is Opexa entering into a collaboration, partnership or other strategic arrangement involving US rights for Tcelna. The performance criteria for the second key milestone was met on February 4, 2013 and vesting has commenced for the second tranche of 95,970 shares.
- [F3]All share numbers and the exercise price have been adjusted to reflect the one-for-four reverse stock split implemented December 14, 2012.